Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Phase I study of perillyl alcohol in patients with refractory malignancies.

Murren JR, Pizzorno G, DiStasio SA, McKeon A, Peccerillo K, Gollerkari A, McMurray W, Burtness BA, Rutherford T, Li X, Ho PT, Sartorelli A.

Cancer Biol Ther. 2002 Mar-Apr;1(2):130-5.

PMID:
12170772
2.

Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.

Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Binger K, Tutsch KD, Pomplun M, Wahamaki A, Marnocha R, Wilding G, Bailey HH.

Clin Cancer Res. 2000 Feb;6(2):390-6.

3.

Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.

Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM, Langer CJ, Litwin S, Yeslow G, Halberr T, Qian M, Gallo JM.

Clin Cancer Res. 2000 Aug;6(8):3071-80.

4.

Phase I clinical trial of perillyl alcohol administered daily.

Ripple GH, Gould MN, Stewart JA, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Pomplun M, Wilding G, Bailey HH.

Clin Cancer Res. 1998 May;4(5):1159-64.

5.

A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.

Bailey HH, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Marnocha R, Holstein SA, Stewart J, Lewis KA, Hohl RJ.

Cancer Chemother Pharmacol. 2004 Oct;54(4):368-76. Epub 2004 Jun 15.

PMID:
15205914
6.

Phase I trial of perillyl alcohol administered four times daily continuously.

Morgan-Meadows S, Dubey S, Gould M, Tutsch K, Marnocha R, Arzoomanin R, Alberti D, Binger K, Feierabend C, Volkman J, Ellingen S, Black S, Pomplun M, Wilding G, Bailey H.

Cancer Chemother Pharmacol. 2003 Nov;52(5):361-6. Epub 2003 Aug 2.

PMID:
12904896
7.

Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.

Vigushin DM, Poon GK, Boddy A, English J, Halbert GW, Pagonis C, Jarman M, Coombes RC.

Cancer Chemother Pharmacol. 1998;42(2):111-7.

PMID:
9654110
8.

A phase I trial of perillyl alcohol in patients with advanced solid tumors.

Azzoli CG, Miller VA, Ng KK, Krug LM, Spriggs DR, Tong WP, Riedel ER, Kris MG.

Cancer Chemother Pharmacol. 2003 Jun;51(6):493-8. Epub 2003 Apr 15.

PMID:
12695855
9.

A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96.

Bailey HH, Levy D, Harris LS, Schink JC, Foss F, Beatty P, Wadler S.

Gynecol Oncol. 2002 Jun;85(3):464-8.

PMID:
12051875
11.
12.

A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.

Delaunoit T, Burch PA, Reid JM, Camoriano JK, Kobayash T, Braich TA, Kaur JS, Rubin J, Erlichman C.

Invest New Drugs. 2006 Jul;24(4):327-33.

PMID:
16502355
13.

The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor.

Holen K, Saltz LB, Hollywood E, Burk K, Hanauske AR.

Invest New Drugs. 2008 Feb;26(1):45-51. Epub 2007 Oct 9.

PMID:
17924057
14.

Perillyl alcohol: applications in oncology.

Belanger JT.

Altern Med Rev. 1998 Dec;3(6):448-57. Review.

15.

Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer.

Meadows SM, Mulkerin D, Berlin J, Bailey H, Kolesar J, Warren D, Thomas JP.

Int J Gastrointest Cancer. 2002;32(2-3):125-8.

PMID:
12794248
16.

Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.

Schöffski P, Thate B, Beutel G, Bolte O, Otto D, Hofmann M, Ganser A, Jenner A, Cheverton P, Wanders J, Oguma T, Atsumi R, Satomi M.

Ann Oncol. 2004 Apr;15(4):671-9.

17.
18.
19.

Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.

Stevenson JP, Sun W, Gallagher M, Johnson R, Vaughn D, Schuchter L, Algazy K, Hahn S, Enas N, Ellis D, Thornton D, O'Dwyer PJ.

Clin Cancer Res. 2002 Aug;8(8):2524-9.

20.
Items per page

Supplemental Content

Write to the Help Desk